Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study
- 10 February 2021
- journal article
- research article
- Published by Elsevier BV in The Lancet. Respiratory Medicine
- Vol. 9 (7), 733-746
- https://doi.org/10.1016/s2213-2600(20)30510-5
Abstract
No abstract availableKeywords
Funding Information
- Vertex Pharmaceuticals
This publication has 37 references indexed in Scilit:
- Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosisEuropean Respiratory Journal, 2011
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Proceedings of the National Academy of Sciences of the United States of America, 2011
- Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosisThorax, 2011
- Hepatic safety of antibiotics used in primary careJournal of Antimicrobial Chemotherapy, 2011
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proceedings of the National Academy of Sciences of the United States of America, 2009
- Clinical phenotype of cystic fibrosis patients with the G551D mutationQJM: An International Journal of Medicine, 2009
- Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practiceJournal of Cystic Fibrosis, 2008
- Pulmonary function between 6 and 18 years of agePediatric Pulmonology, 1993
- Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutationNature, 1991
- Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNAScience, 1989